image: Fragile X syndrome (FXS), an inherited disorder caused by mutations in a gene critical to normal brain development, is one of the most common causes of intellectual disability and autistic spectrum disorder. Results from clinical trials show that a promising drug for FXS has no effect on patients' behavior. This material relates to a paper that appeared in the 13 January 2016 issue of Science Translational Medicine, published by AAAS. The paper, by E. Berry-Kravis at Rush University Medical Center in Chicago, IL, and colleagues was titled, "Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials." view more
Credit: V. Altounian / <i>Science Translational Medicine</i>